Ovarian Cancer Trial, Recruiting NCT06543537 Sponsor: Dana-Farber Cancer Institute Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT06543537
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For patients:

  • Adults aged 18 or older
  • People who can speak, understand, and respond to questions written in English
  • People who are willing to have conversations audio recorded
  • People who have been diagnosed with advanced ovarian cancer (stage III, stage IV, or cancer that has come back)
  • People who are under the care of a participating doctor and nurse/physician assistant pair involved in this trial
  • People who are scheduled to receive chemotherapy during the recruitment period
  • People who are already signed up, or willing to sign up, for Patient Gateway (an online patient portal)

For caregivers:

  • Adults aged 18 or older
  • People who can speak, understand, and respond to questions written in English
  • People who are willing to have conversations audio recorded
  • People who are a family member, partner, or friend of a patient in this trial, and someone that patient talks to about their cancer care

For clinicians:

  • Doctors, nurse practitioners, or physician assistants employed at Dana-Farber Cancer Institute (DFCI)
  • Clinicians who see at least 4 patients per month with advanced ovarian cancer in an outpatient setting

Who may not be able to join:

  • People under the age of 18
  • People who are not able to give their own consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rachel Pozzar, PhD, Dana-Farber Cancer Institute

Phone: 857-215-0743

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
17 January 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Enrollment Rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov